|
SCFD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.99209999995897E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.14619999947286E-07 |
| Normal-vs-Stage2 |
1.064200E-01 |
| Normal-vs-Stage3 |
5.60530000000004E-05 |
| Normal-vs-Stage4 |
1.76330000001279E-06 |
| Stage1-vs-Stage2 |
1.802820E-01 |
| Stage1-vs-Stage3 |
8.211800E-01 |
| Stage1-vs-Stage4 |
1.735250E-01 |
| Stage2-vs-Stage3 |
1.761200E-01 |
| Stage2-vs-Stage4 |
4.926200E-02 |
| Stage3-vs-Stage4 |
3.370400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.38430000024204E-07 |
| Normal-vs-AfricanAmerican |
1.734240E-02 |
| Normal-vs-Asian |
2.19189999999259E-05 |
| Caucasian-vs-AfricanAmerican |
4.429800E-01 |
| Caucasian-vs-Asian |
4.803000E-01 |
| AfricanAmerican-vs-Asian |
2.645600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.87279999996903E-06 |
| Normal-vs-Female |
1.85958999999736E-05 |
| Male-vs-Female |
1.673390E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.62879999990417E-07 |
| Normal-vs-Age(41-60Yrs) |
4.21950000000226E-05 |
| Normal-vs-Age(61-80Yrs) |
2.648100E-04 |
| Normal-vs-Age(81-100Yrs) |
6.173800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.105800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.992800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.040000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.842400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.693200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.172400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.411800E-02 |
| Classical-VS-Follicular |
6.168200E-01 |
| Classical-VS-Other |
3.226000E-02 |
| Classical-VS-Normal |
1.66472999999501E-05 |
| Tall-VS-Follicular |
6.761700E-02 |
| Tall-VS-Other |
1.985580E-01 |
| Tall-VS-Normal |
2.29339999999745E-05 |
| Follicular-VS-Other |
7.497700E-02 |
| Follicular-VS-Normal |
5.600200E-03 |
| Other-VS-Normal |
4.428700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.607600E-04 |
| Normal-vs-N1 |
3.18189999903851E-08 |
| N0-vs-N1 |
1.369990E-02 |
|
|
